IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 4, 2008, Pages 277-285

  Vethe, N T ^a,b   Bremer, S ^a,b   Bergan, S ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

6 thioguanosine; IMPDH; Inosine monophosphate dehydrogenase; MPA; Mycophenolic acid; Purine nucleotides; Thiopurine nucleotides

Indexed keywords

INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; PURINE NUCLEOTIDE; THIOGUANOSINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, LEUKEMIC; GUANOSINE; HUMANS; IMP DEHYDROGENASE; INTRACELLULAR SPACE; LEUKEMIA; MYCOPHENOLIC ACID; PURINES; THIONUCLEOSIDES;

EID: 46949083791     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701724871     Document Type: Article

References (25)

1. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268:27286-90.
2. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113:515-24.
3. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995;49:1323-9.
4. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34:738-46.
5. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990;265:5292-5.
6. Senda M, Natsumeda Y. Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). Life Sci 1994;54:1917-26.
7. Zimmermann AG, Gu JJ, Laliberte J, Mitchell BS. Inosine-5′- monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog Nucleic Acid Res Mol Biol 1998;61:181-209.
8. Jain J, Almquist SJ, Ford PJ, Shlyakhter D, Wang Y, Nimmesgern E, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 2004;67:767-76.
9. Glesne DA, Collart FR, Huberman E. Regulation of IMP dehydrogenase gene expression by its end products, guanine nucleotides. Mol Cell Biol 1991;11:5417-25.
10. Griesmacher A, Weigel G, Seebacher G, Muller MM. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997;43:2312-7.
11. Stet EH, De Abreu RA, Bokkerink JP, Lambooy LH, Vogels-Mentink TM, Keizer-Garritsen JJ, et al. Inhibition of IMP dehydrogenase by mycophenolic acid in Molt F4 human malignant lymphoblasts. Ann Clin Biochem 1994;31 Pt 2:174-80.
12. Vethe NT, Bergan S. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy. Ther Drug Monit 2006;28:608-13.
13. Bremer S, Rootwelt H, Bergan S. Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem 2007;53:1023-9.
14. Jagodzinski P, Lizakowski S, Smolenski RT, Slominska EM, Goldsmith D, Simmonds HA, et al. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes. Clin Sci (Lond) 2004;107:69-74.
15. Ruckemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated Tlymphocytes from healthy humans. J Biol Chem 1998;273:21682-91.
16. Weimert NA, Derotte M, Alloway RR, Woodle ES, Vinks AA. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 2007;29:141-9.
17. Brouwer C, Vermunt-de Koning DG, Trueworthy RC, Ter Riet PG, Duley JA, Trijbels FJ, et al. Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects. Pediatr Blood Cancer 2006;46:434-8.
18. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339-48.
19. Ji Y, Gu J, Makhov AM, Griffith JD, Mitchell BS. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J Biol Chem 2005;281:206-12.
20. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005;80:S181-90.
21. Daxecker H, Raab M, Cichna M, Markl P, Muller MM. Determination of the effects of mycophenolic acid on the nucleotide pool of human peripheral blood mononuclear cells in vitro by high-performance liquid chromatography. Clin Chim Acta 2001;310:81-7.
22. Qiu Y, Fairbanks LD, Ruckermann K, Hawrlowicz CM, Richards DF, Kirschbaum B, et al. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes. Transplantation 2000;69:890-7.
23. Devyatko E, Zuckermann A, Bohdjalian A, Roedler S, Dunkler D, Grimm M, et al. Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil. Transplantation 2006;82:113-18.
24. Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, Simmonds HA. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond) 2004;107:63-8.
25. Weigel G, Griesmacher A, Zuckermann AO, Laufer G, Mueller MM. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001;69:137-44.